Hamostaseologie最新文献_第2页

iTTP in der Schwangerschaft: Erfolgreiche Behandlung mit Caplacizumab. 妊娠期 iTTP：卡普珠单抗的成功治疗。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-10-23 DOI: 10.1055/s-0044-1791987

引用次数: 0

Komplementdysregulation als Biomarker für Post Covid. 补体失调是后 Covid 的生物标志物。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-10-23 DOI: 10.1055/s-0044-1791988

引用次数: 0

Be Curious. Try New Things. 要有好奇心。尝试新事物。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-10-28 DOI: 10.1055/a-2316-4116

Johannes Thaler

引用次数: 0

Utility of Global Hemostatic Assays in Patients with Bleeding Disorders of Unknown Cause. 全球止血检测对不明原因出血患者的实用性。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-07-01 DOI: 10.1055/a-2330-9112

Dino Mehic, Alice Assinger, Johanna Gebhart

{"title":"Utility of Global Hemostatic Assays in Patients with Bleeding Disorders of Unknown Cause.","authors":"Dino Mehic, Alice Assinger, Johanna Gebhart","doi":"10.1055/a-2330-9112","DOIUrl":"10.1055/a-2330-9112","url":null,"abstract":"Bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion after exhaustive evaluation of plasmatic coagulation and platelet function. This review explores the utility of global hemostatic assays as confirmatory tests and in elucidating the pathophysiology of BDUC. Unlike traditional hemostatic tests that focus on coagulation factors, global assays are conducted both in plasma and also whole blood. These assays provide a more comprehensive understanding of the cell-based model of coagulation, aid in the identification of plasmatic factor abnormalities that may reduce hemostatic capacity, and allow for the assessment of impaired platelet-endothelial interactions under shear stress, as well as hyperfibrinolytic states. While clinical tests such as skin bleeding time and global assays such as PFA-100 exhibit limited diagnostic capacity, the role of viscoelastic testing in identifying hemostatic dysfunction in patients with BDUC remains unclear. Thrombin generation assays have shown variable results in BDUC patients; some studies demonstrate differences compared with healthy controls or reference values, whereas others question its clinical utility. Fibrinolysis assessment in vitro remains challenging, with studies employing euglobulin clot lysis time, plasma clot lysis time, and fluorogenic plasmin generation yielding inconclusive or conflicting results. Notably, recent studies suggest that microfluidic analysis unveils shear-dependent platelet function defects in BDUC patients, undetected by conventional platelet function assays. Overall, global assays might be helpful for exploring underlying hemostatic impairments, when conventional hemostatic laboratory tests yield no results. However, due to limited data and/or discrepant results, further research is needed to evaluate the utility of global assays as screening tools.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141478019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigations on the Hemostatic Potential of Physiological Body Fluids. 关于生理体液止血潜能的研究。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-10-23 DOI: 10.1055/a-2374-2903

Johannes Thaler, Carla Tripisciano, Rienk Nieuwland

引用次数: 0

Die Gesellschaft für Thrombose- und Hämostaseforschung e.V. informiert. 血栓与止血研究学会通报。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-10-23 DOI: 10.1055/s-0044-1791986

引用次数: 0

Management of Recurrent Venous Thromboembolism in Severe Immune Thrombocytopenia: A Case Report and a Review of the Literature. 严重免疫性血小板减少症复发性静脉血栓栓塞的治疗：一例报告和文献复习。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2023-10-31 DOI: 10.1055/a-2159-8722

Mathias Haargaard Nielsen, Mustafa Vakur Bor

引用次数: 0

Bleeding Risk in Patients with Cancer. 癌症患者的出血风险。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-09-03 DOI: 10.1055/a-2347-6507

Cornelia Englisch, Nikola Vladic, Cihan Ay

{"title":"Bleeding Risk in Patients with Cancer.","authors":"Cornelia Englisch, Nikola Vladic, Cihan Ay","doi":"10.1055/a-2347-6507","DOIUrl":"https://doi.org/10.1055/a-2347-6507","url":null,"abstract":"The hemostatic system and cancer display a tight interconnection, and hemostatic imbalance frequently occurs in patients with cancer. While extensive knowledge about thrombotic risk has been generated, less is known about bleeding risk and associated risk factors. However, bleeding risk is of high significance as patients with cancer frequently receive therapeutic anticoagulation for various indications and/or are candidates for primary thromboprophylaxis. The risk of bleeding in patients with cancer is variable and difficult to assess in clinical practice. Certain clinical settings such as hospitalization, specific underlying risk factors (e.g., tumor type), and medications (e.g., anticoagulation) can contribute to the individual bleeding risk of a patient with cancer. In addition, some dynamic factors such as platelet count or kidney function have an impact. Particularly, data on baseline risk of bleeding are lacking to allow for risk assessment in cancer patients without anticoagulation. In contrast, risk assessment models for the prediction of bleeding events in cancer patients receiving anticoagulation have been developed; however, these have yet to be validated. The recognition of the importance of bleeding risk in cancer patients is growing, leading to an increasing number of studies investigating and reporting bleeding complications. As study designs and reporting of bleeding events vary, it is challenging to offer a clear synthesis of evidence. In this narrative review, we provide an overview of currently available data about incidence, risk factors, and clinical impact of bleeding events in patients with cancer, and critically review risk assessment models for bleeding in cancer patients during anticoagulant therapy.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic Venous Disease: Pathophysiological Aspects, Risk Factors, and Diagnosis. 慢性静脉疾病：病理生理学方面、风险因素和诊断。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-07-11 DOI: 10.1055/a-2315-6206

Philip Kienzl, Julia Deinsberger, Benedikt Weber

引用次数: 0

Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics. 儿科使用血小板生成素受体激动剂的最新情况。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-06-26 DOI: 10.1055/a-2247-4209

Jennifer Gebetsberger, Werner Streif, Christof Dame

{"title":"Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics.","authors":"Jennifer Gebetsberger, Werner Streif, Christof Dame","doi":"10.1055/a-2247-4209","DOIUrl":"10.1055/a-2247-4209","url":null,"abstract":"This review summarizes the rationale and current data on the use of thrombopoietin receptor agonists (TPO-RAs) for treating severe thrombocytopenia in infants, children, and adolescents. It focuses on substances that have been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for pediatric patients. Romiplostim and eltrombopag are already established as second-line treatment for persistent or chronic immune thrombocytopenia (ITP). As in adults, TPO-RAs are currently also evaluated in severe aplastic anemia (SAA), chemotherapy-induced thrombocytopenia (CIT), myelodysplastic syndromes (MDS), and poor engraftment after hematopoietic stem cell transplantation in pediatric and adolescent patients. Moreover, studies on the implication of TPO-RA in treating rare inherited thrombocytopenias, such as Wiskott-Aldrich syndrome (WAS), congenital amegakaryocytic thrombocytopenia (CAMT), or MYH9-associated thrombocytopenia, deserve future attention. Current developments include testing of avatrombopag and lusutrombopag that are approved for the treatment of thrombocytopenia associated with chronic liver disease (CLD) in adult patients. In pediatric and adolescent medicine, we expect in the near future a broader use of TPO-RAs as first-line treatment in primary ITP, thereby considering immunomodulatory effects that increase the rate of sustained remission off-treatment, and a selective use in rare inherited thrombocytopenias based on current clinical trials.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141460879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0